Abstract: Non-small cell lung cancer （NSCLC) is the most common histological lung cancer type and is associated with distant metastases in approximately 66% of patients at the time of diagnosis. The brain is a common site of metastasis, and intracranial involvement is detected in approximately 13% of patients at the initial diagnosis. This severely affects quality of life and leads to a poor prognosis. Targeted therapy in patients with driver gene-positive NSCLC brain metastases achieves better intracranial control rates; however, treatment options for patients with driver gene-negative NSCLC brain metastases are limited. In recent years, with the expansion of immunotherapy, immune checkpoint inhibitors (ICIs) have been widely used in clinical practice. The therapeutic modality of ICIs combined with radiotherapy shows promise in the treatment of patients with driver gene-negative NSCLC brain metastases. This article reviews the clinical research progress of radiotherapy combined with immunotherapy in patients with sensitive driver gene-negative NSCLC brain metastases, the aim of providing a reference for available clinical treatment options.